Page 30 - Ioscience News Today

Toronto, Ontario--(Newsfile Corp. - August 27, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos") announced today that they have successfully determined a high resolution (1.85Å) X-ray crystal

Toronto, Ontario--(Newsfile Corp. - August 13, 2021) - Satellos Bioscience Inc. (formerly iCo Therapeutics Inc.) (TSXV: MSCL) ("Satellos" or the "Company") is pleased to announce the completion, following

Seoul [South Korea], August 11 (ANI/Global Economic): South Korean Bioscience's vaccine for COVID-19 has entered Phase 3 clinical trials for the first time as the vaccine developed in Korea.

Keego Harbor, Michigan--(Newsfile Corp. - August 11, 2021) - ZIVO Bioscience (NASDAQ: ZIVO) today announced that Andrew Dahl will be attending the Q3 Virtual Investor Summit. Event Q3 Investor Summit

The leading professional body representing many of the learned societies and other organisations making up the diverse landscape of the biological sciences, as well as thousands of individuals

DJ Clinical portfolio update Arix Bioscience PLC (ARIX) Clinical portfolio update 11-Jun-2021 / 13:05 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is

DJ Transaction in own shares Arix Bioscience PLC (ARIX) Transaction in own shares 10-Jun-2021 / 17:25 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is

Lexaria Bioscience Corp.: Lexaria Provides Progress Report on Six R&D Programs All studies are using DehydraTECH 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine These studies are part of Lexarias 2021 applied R&D program intended to enable opportunities for strategic partnerships KELOWNA, BC / ACCESSWIRE / June 9, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator...

Alligator Bioscience (Nasdaq Stockholm: ATORX) today presents novel supportive data from the ongoing Phase I clinical trial with the 4-1BB (CD137) drug candidate ATOR-1017 developed as tumor-directed therapy for metastatic cancer. The results, presented in a poster presentation at the 2021 ASCO Annual Meeting, validate the therapeutic potential of ATOR-1017 demonstrating a very favorable safety profile combined with clear signs of proof of mechanism, as activation of T cells in the circulation w

DJ Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO Annual Meeting Arix Bioscience PLC (ARIX) Harpoon presents updated interim clinical data for HPN424 at the 2021 ASCO